Daniel Finke1,2, Markus B Heckmann1,2, Esther Herpel3, Hugo A Katus1,2, Uwe Haberkorn4,5,6, Florian Leuschner1,2, Lorenz H Lehmann1,2,7. 1. Department of Cardiology, University Hospital Heidelberg, Heidelberg, Germany. 2. DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, Germany. 3. Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany. 4. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. 5. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. 6. Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany. 7. German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract
Objective: Checkpoint inhibitors (ICIs) have gained importance in recent years regarding the treatment of a variety of oncologic diseases. The possibilities of diagnosing cardiac adverse autoimmune effects of ICIs are still limited. We aimed to implement FAPI PET/CT imaging in detecting ICI-associated myocarditis. Methods: In a retrospective study, FAPI PET/CT scans of 26 patients who received ICIs from 01/2017 to 10/2019 were analyzed. We compared tracer enrichment in the heart of patients without any signs of a cardiac disease (n = 23) to three patients with suspected ICI-associated myocarditis. To exclude any significant coronary heart disease, cardiac catherization was performed. All three patients' myocardial biopsies were examined for inflammatory cells. Results: Three patients showed clinical manifestations of an ICI syndrome including myocarditis with elevated levels of hsTnT (175 pg/ml, 1,771 pg/ml, 157 pg/ml). Further cardiological assessments revealed ECG abnormalities, lymphocyte infiltration of the myocardium in the biopsies or wall motion abnormalities in echocardiography. These patients' FAPI PET/CTs showed cardiac enrichment of the marker which was less distinct or absent in patients receiving ICIs without any signs of immunological adverse effects or cardiac impairment (n = 23) [Median SUV myocarditis patients: 1.79 (IQR: 1.65, 1.85), median SUV non-myocarditis patients: 1.15 (IQR: 0.955, 1.52)]. Conclusions: Apart from the successful implementation of ICIs in oncological treatments, ICI-associated myocarditis is still a challenging adverse effect. FAPI PET/CT may be used in order to identify affected patients at an early stage. Moreover, when integrated into cancer stage diagnostics, it contributes to cardiac risk stratification besides biomarker, ECG and echocardiography.
Objective: Checkpoint inhibitors (ICIs) have gained importance in recent years regarding the treatment of a variety of oncologic diseases. The possibilities of diagnosing cardiac adverse autoimmune effects of ICIs are still limited. We aimed to implement FAPI PET/CT imaging in detecting ICI-associated myocarditis. Methods: In a retrospective study, FAPI PET/CT scans of 26 patients who received ICIs from 01/2017 to 10/2019 were analyzed. We compared tracer enrichment in the heart of patients without any signs of a cardiac disease (n = 23) to three patients with suspected ICI-associated myocarditis. To exclude any significant coronary heart disease, cardiac catherization was performed. All three patients' myocardial biopsies were examined for inflammatory cells. Results: Three patients showed clinical manifestations of an ICI syndrome including myocarditis with elevated levels of hsTnT (175 pg/ml, 1,771 pg/ml, 157 pg/ml). Further cardiological assessments revealed ECG abnormalities, lymphocyte infiltration of the myocardium in the biopsies or wall motion abnormalities in echocardiography. These patients' FAPI PET/CTs showed cardiac enrichment of the marker which was less distinct or absent in patients receiving ICIs without any signs of immunological adverse effects or cardiac impairment (n = 23) [Median SUV myocarditispatients: 1.79 (IQR: 1.65, 1.85), median SUV non-myocarditispatients: 1.15 (IQR: 0.955, 1.52)]. Conclusions: Apart from the successful implementation of ICIs in oncological treatments, ICI-associated myocarditis is still a challenging adverse effect. FAPI PET/CT may be used in order to identify affected patients at an early stage. Moreover, when integrated into cancer stage diagnostics, it contributes to cardiac risk stratification besides biomarker, ECG and echocardiography.
Authors: Ornella Leone; John P Veinot; Annalisa Angelini; Ulrik T Baandrup; Cristina Basso; Gerald Berry; Patrick Bruneval; Margaret Burke; Jagdish Butany; Fiorella Calabrese; Giulia d'Amati; William D Edwards; John T Fallon; Michael C Fishbein; Patrick J Gallagher; Marc K Halushka; Bruce McManus; Angela Pucci; E René Rodriguez; Jeffrey E Saffitz; Mary N Sheppard; Charles Steenbergen; James R Stone; Carmela Tan; Gaetano Thiene; Allard C van der Wal; Gayle L Winters Journal: Cardiovasc Pathol Date: 2011-12-03 Impact factor: 2.185
Authors: Thomas Lindner; Anastasia Loktev; Annette Altmann; Frederik Giesel; Clemens Kratochwil; Jürgen Debus; Dirk Jäger; Walter Mier; Uwe Haberkorn Journal: J Nucl Med Date: 2018-04-06 Impact factor: 10.057
Authors: Manuel Röhrich; Ralf Floca; Lisa Loi; Sebastian Adeberg; Paul Windisch; Frederik L Giesel; Clemens Kratochwil; Paul Flechsig; Hendrik Rathke; Thomas Lindner; Anastasia Loktev; Heinz Peter Schlemmer; Uwe Haberkorn; Daniel Paech Journal: Eur J Radiol Date: 2020-04-20 Impact factor: 3.528
Authors: Yan Huang; Avis E Simms; Anna Mazur; Sophie Wang; Noel R León; Barry Jones; Nazneen Aziz; Thomas Kelly Journal: Clin Exp Metastasis Date: 2011-05-22 Impact factor: 5.150
Authors: Daniel Y Wang; Joe-Elie Salem; Justine V Cohen; Sunandana Chandra; Christian Menzer; Fei Ye; Shilin Zhao; Satya Das; Kathryn E Beckermann; Lisa Ha; W Kimryn Rathmell; Kristin K Ancell; Justin M Balko; Caitlin Bowman; Elizabeth J Davis; David D Chism; Leora Horn; Georgina V Long; Matteo S Carlino; Benedicte Lebrun-Vignes; Zeynep Eroglu; Jessica C Hassel; Alexander M Menzies; Jeffrey A Sosman; Ryan J Sullivan; Javid J Moslehi; Douglas B Johnson Journal: JAMA Oncol Date: 2018-12-01 Impact factor: 31.777
Authors: Haig Aghajanian; Toru Kimura; Joel G Rurik; Aidan S Hancock; Michael S Leibowitz; Li Li; John Scholler; James Monslow; Albert Lo; Wei Han; Tao Wang; Kenneth Bedi; Michael P Morley; Ricardo A Linares Saldana; Nikhita A Bolar; Kendra McDaid; Charles-Antoine Assenmacher; Cheryl L Smith; Dagmar Wirth; Carl H June; Kenneth B Margulies; Rajan Jain; Ellen Puré; Steven M Albelda; Jonathan A Epstein Journal: Nature Date: 2019-09-11 Impact factor: 49.962
Authors: Frederik L Giesel; Clemens Kratochwil; Thomas Lindner; Manfred M Marschalek; Anastasia Loktev; Wencke Lehnert; Jürgen Debus; Dirk Jäger; Paul Flechsig; Annette Altmann; Walter Mier; Uwe Haberkorn Journal: J Nucl Med Date: 2018-08-02 Impact factor: 10.057
Authors: Markus B Heckmann; Finn Reinhardt; Daniel Finke; Hugo A Katus; Uwe Haberkorn; Florian Leuschner; Lorenz H Lehmann Journal: Circ Cardiovasc Imaging Date: 2020-09-11 Impact factor: 7.792
Authors: David Kersting; Stephan Settelmeier; Ilektra-Antonia Mavroeidi; Ken Herrmann; Robert Seifert; Christoph Rischpler Journal: Int J Mol Sci Date: 2022-03-30 Impact factor: 5.923